| Citation |
BALIAKAS, Panagiotis, Anna PUIGGROS, Aliki XOCHELLI, Lesley-Ann
SUTTON, Florence NGUYEN-KHAC, Anne GARDINER, Karla PLEVOVÁ, Eva
MINGA, Anastasia HADZIDIMITRIOU, Renata WALEWSKA, Helen
MCCARTHY, Margarita ORTEGA, Rosa COLLADO, Teresa GONZALEZ,
Isabel GRANADA, Elisa LUNO, Jana KOTAŠKOVÁ, Theodoros
MOYSIADIS, Zadie DAVIS, Niki STAVROYIANNI, Achilles
ANAGNOSTOPOULOS, Jonathan C. STREFFORD, Šárka POSPÍŠILOVÁ,
Frederic DAVI, Anastasia ATHANASIADOU, Richard ROSENQUIST,
David OSCIER, Blanca ESPINET and Kostas STAMATOPOULOS.
Additional trisomies amongst patients with chronic lymphocytic
leukemia carrying trisomy 12: the accompanying chromosome makes
a difference. Haematologica. PAVIA: FERRATA STORTI FOUNDATION,
2016, vol. 101, No 7, p. 299-302. ISSN 0390-6078. Available
from: https://dx.doi.org/10.3324/haematol.2015.140202. |
| Description |
Recurrent cytogenetic abnormalities in chronic lym- phocytic leukemia (CLL), namely deletions of chromo- somes 11q, 13q, 17p and trisomy 12 (+12), define sub- groups of patients with different clinical behavior and response to treatment. 1 We and others previously report- ed a minor proportion of CLL cases with co-existing tri- somies of chromosomes 12 and 19 who share specific clinico-biological characteristics. 2-4 However, since the cohort was small, no definitive conclusions could be drawn. Here, we analyzed a large, multi-institutional series. We confirm and significantly extend previous observations through the identification of subgroups of +12 CLL cases harboring particular concurrent trisomies demonstrating distinctive clinico-biological profiles. We analyzed an unselected cohort of 4486 CLL patients with available classic cytogenetic (n=4285) or high-density 250K single nucleotide polymorphism (SNP)-array (n=201) data. We identified 712 cases (16% of the cohort) carrying +12. 5 Median time from diagnosis to cytogenet- ic/SNP analysis was 1.5 months (range 0-194); the major- ity of cases included in survival analysis were untreated prior to testing (94%). The study was approved by the local Ethics Review Committees. Details of the study cohort and the methodologies used are provided in the Online Supplementary Appendix.
|
